for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jiangsu Hengrui Medicine Co Ltd

600276.SS

Latest Trade

81.50CNY

Change

1.36(+1.70%)

Volume

26,180,800

Today's Range

80.00

 - 

83.44

52 Week Range

41.48

 - 

83.44

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
80.14
Open
80.14
Volume
26,180,800
3M AVG Volume
358.34
Today's High
83.44
Today's Low
80.00
52 Week High
83.44
52 Week Low
41.48
Shares Out (MIL)
4,422.81
Market Cap (MIL)
354,444.30
Forward P/E
67.11
Dividend (Yield %)
0.10

Next Event

Q3 2019 Jiangsu Hengrui Medicine Co Ltd Earnings Release

Latest Developments

More

Jiangsu Hengrui Medicine Says H1 Net Profit Up 26.3% Y/Y

Jiangsu Hengrui Medicine's 2018 Net Profit Up 25.61 Percent Y/Y 1.19 Billion Yuan

Jiangsu Hengrui Medicine Says Its 2018 Net Profit Up 26.4 Percent Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Jiangsu Hengrui Medicine Co Ltd

JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No.7 Kunlunshan Road

Lianyungang Eco & Tech Development Zone

+86.518.81220983

http://www.hrs.com.cn

Executive Leadership

Piaoyang Sun

Chairman of the Board

Xinhua Jiang

Vice Chairman of the Board

Song Zhou

Chief Financial Officer

Yunshu Zhou

General Manager, Director

Sumei Jiang

Executive Deputy General Manager, Director

Key Stats

1.62 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

11.1K

2017

13.8K

2018

17.4K

2019(E)

22.4K
EPS (CNY)

2016

0.589

2017

0.728

2018

0.917

2019(E)

1.194
Price To Earnings (TTM)
77.76
Price To Sales (TTM)
18.01
Price To Book (MRQ)
16.28
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.10
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
23.22
Return on Equity (TTM)
20.37

Latest News

BRIEF-Jiangsu Hengrui Medicine unit passes U.S. FDA approval

* Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Health and Youth Care Inspectorate

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine gets approval for clinical trials of drugs

* Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's 9-month net profit up 20.7 pct y/y

* Says 9-month net profit up 20.7 percent y/y at 2.3 billion yuan ($347.33 million)

BRIEF-Jiangsu Hengrui Medicine passes FDA approval

* Says it received approval for its cisatracurium besilate injection from U.S Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's H1 net profit up 19.7 pct y/y

* Says H1 net profit up 19.7 percent y/y at 1.6 billion yuan ($242.26 million)

BRIEF-Jiangsu Hengrui Medicine and unit plans clinical trail for new drug SHR0302

* Says it and unit plans to start clinical trail for new drug SHR0302, which is a kind of selective depressant used for treatment of rheumatoid arthritis

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Docetaxel Injection from U.S Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's main product enters into National health insurance's list

* Says its main product ApatinibMesylate Tablets, a oral absorption, has been listed on National health insurance's list

BRIEF-Jiangsu Hengrui Medicine to pay A shares annual div for FY 2016 on May 31

* Says it will pay cash dividend of 0.135 yuan(before tax)/share and use additional paid-in capital to distribute 0.2 new shares/share for 2016 to shareholders of record on May 26

BRIEF-Jiangsu Hengrui Medicine's Q1 net profit up 18.6 pct y/y

* Says Q1 net profit up 18.6 pct y/y at 811.8 million yuan ($117.92 million)

BRIEF-Jiangsu Hengrui Medicine to set up unit with registered capital of 1.5 bln yuan

* Says it plans to set up medicine unit with registered capital at 1.5 billion yuan ($217.89 million)

BRIEF-Jiangsu Hengrui Medicine receives new drug license

* Says the co received new drug license for Caspofungin Acetate for Injection, getting approval to sell it in UK and Germany

BRIEF-Jiangsu Hengrui Medicine announces FY 2016 dividend payment

* Says it plans to use undistributed profits to pay a cash dividend of 1.35 yuan (pre-tax) per 10 shares to shareholders for FY 2016

BRIEF-Jiangsu Hengrui Medicine's 2016 net profit up 19.2 pct

* Says its 2016 net profit up 19.2 percent y/y at 2.6 billion yuan ($376.08 million)

BRIEF-Jiangsu Hengrui Medicine and unit get approval for drug clinical trial

* Says the co and its unit received approval from China Food and Drug Administration to start new drug SHR-1309 injection clinical trial

BRIEF-Jiangsu Hengrui Medicine passes FDA approval

* Says co received approval for its Cisatracurium Besylate injection from U.S Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine and unit commence phase I clinical trial for SHR-1314

* Says the co and its unit commenced phase I clinical trial for injection SHR-1314

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up